Edgewise Therapeutics Inc (EWTX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Edgewise Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 38.40 $ — 72% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
2 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year -74.9% failed
- Share count grows by less than 3% a year 24.3% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 526 m net cash passed
- Operating cash flow covers the profits of the last three years 57 m failed
- Return on capital at 15% or higher, or up versus two years ago -36.4% failed
- Insiders hold at least 10% or are net buyers 0.5% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 30.0% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 10
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.23 | -2.34 – 8.31 | 209 | 85.6% | 6 |
| 12/31/2027 | -1.47 | -2.46 – -0.36 | 53 | -528.6% | 8 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.48 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.43 | – | 2 | -6.00 | -1,872.60 | -27 | -27 |
| 2025: Q1 | -0.43 | – | 0 | – | – | -38 | -38 |
| 2025: Q2 | -0.34 | – | 0 | – | – | -33 | -33 |
| 2025: Q3 | -0.39 | – | 0 | – | – | -35 | -35 |
| 2025: Q4 | -0.49 | – | 0 | -100.00 | – | -39 | -38 |
| 2026: Q1 | -0.46 | – | 0 | – | – | -43 | -43 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | 0 | -10 | -9 | -0.19 | -9 | -17 | 25 |
| 2020 | 0 | -17 | -17 | -0.35 | -15 | -33 | 131 |
| 2021 | 0 | -43 | -42 | -0.85 | -34 | 274 | 285 |
| 2022 | 0 | -22 | -15 | -0.29 | -53 | 347 | 367 |
| 2023 | 0 | -114 | -100 | -1.57 | -92 | 319 | 340 |
| 2024 | 0 | -159 | -134 | -1.45 | -109 | 459 | 487 |
| 2025 | 0 | -191 | -168 | -1.63 | -144 | 522 | 553 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Edgewise Therapeutics, Inc., ein biopharmazeutisches Unternehmen, entdeckt, entwickelt und vermarktet Therapien zur Behandlung von Muskelerkrankungen.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 154 |
| Headquarters | Boulder, CO |
| Address | 1715 38th Street, 80301 Boulder, United States |
| Phone | 720 262 7002 |
| Website | edgewisetx.com |
| IPO Date | 26. Mar 2021 |
| ISIN | US28036F1057 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Peter A. Thompson FACP, M.D. | Co-Founder & Independent Chairman | 1960 |
| Kevin Koch Ph.D. | President, CEO & Director | 1960 |
| Badreddin Edris Ph.D. | Co-Founder & Independent Director | 1987 |
| Alan J. Russell Ph.D. | Co-Founder, Chief Scientific Officer & Director | 1970 |
| Michael P. Nofi | Chief Financial Officer | 1971 |
| Behrad Derakhshan Ph.D. | Chief Operating Officer | 1980 |
| Joanne M. Donovan M.D., Ph.D. | Chief Medical Officer | 1957 |
| John R. Moore J.D. | General Counsel | 1964 |
| Aylin Tugcu | Senior Vice President of Cardiovascular Clinical Development & Medical Affairs | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.